SMAP - ETF AI Analysis
Top Page
(undefined)
Rating:72Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown solid gains so far this year and over the past month, indicating positive recent momentum.
Leading Winners in Top Holdings
Several of the largest positions, such as Monolithic Power, MKS, and Casey’s General, have delivered strong year-to-date gains that support the fund’s results.
Broad Sector Diversification
Holdings spread across industrials, health care, technology, financials, consumer sectors, and more help reduce the impact of weakness in any single industry.
Negative Factors
High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can eat into long-term returns for investors.
U.S.-Only Geographic Exposure
With almost all assets in U.S. companies, the ETF offers little diversification across different countries and economies.
Notable Underperforming Holdings
Some meaningful positions, including Repligen and a few financial and health care names, have shown weak or negative performance this year, which can drag on overall returns.
SMAP vs. SPDR S&P 500 ETF (SPY)
AUMN/A
RegionN/A
Expense RatioN/A
BetaN/A
IssuerN/A
Inception DateN/A
Dividend YieldN/A
Asset ClassN/A
Index TrackedN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst CoveringN/A
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SMAP Summary
The Amplify Small-Mid Cap Equity ETF (SMAP) focuses on smaller and mid-sized U.S. companies, aiming to tap into the growth potential of businesses that are not yet giants like those in the S&P 500. It doesn’t track a single index, but follows an “extended market” theme across many sectors, including industrials, health care, and technology. Well-known holdings include West Pharmaceutical Services and Steel Dynamics. Investors might consider SMAP for growth and diversification beyond large-cap stocks. However, smaller companies can be more volatile, so the share price can move up and down more sharply than the overall market.
How much will it cost me?The Amplify Small-Mid Cap Equity ETF (SMAP) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, which typically involves more research and trading compared to passively managed funds. Active management aims to outperform the market by selecting specific investments, which can justify the higher cost.
What would affect this ETF?The Amplify Small-Mid Cap Equity ETF (SMAP) could benefit from economic growth and innovation in sectors like technology and industrials, which make up a significant portion of its holdings. However, it may face challenges from rising interest rates or economic slowdowns, which can disproportionately impact smaller companies. Additionally, its U.S.-focused exposure means it is sensitive to domestic economic and regulatory changes.
SMAP Top 10 Holdings
SMAP leans heavily into U.S. small and mid-cap names, with a clear tilt toward industrials, health care, and tech rather than the usual mega-cap crowd. Monolithic Power and MKS are the main engines here, with rising semiconductor demand giving the fund a helpful tailwind. West Pharmaceutical and Steel Dynamics add steady, if sometimes choppy, support from health care and materials. On the flip side, Watsco and Stifel Financial have been lagging, occasionally acting like sandbags on an otherwise nimble, domestically focused portfolio.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Monolithic Power | 4.93% | $65.33K | $76.95B | 130.67% | 75 Outperform | |
| MKS | 3.95% | $52.39K | $21.90B | 285.04% | 75 Outperform | |
| West Pharmaceutical Services | 3.64% | $48.27K | $22.81B | 51.06% | 68 Neutral | |
| Casey's General | 3.30% | $43.73K | $28.35B | 69.45% | 68 Neutral | |
| Curtiss-Wright | 3.16% | $41.87K | $27.62B | 62.44% | 74 Outperform | |
| Steel Dynamics | 3.07% | $40.68K | $37.52B | 92.76% | 76 Outperform | |
| Stifel Financial | 2.68% | $35.46K | $10.76B | 11.70% | 75 Outperform | |
| Eagle Materials | 2.58% | $34.16K | $6.85B | 11.67% | 77 Outperform | |
| Watsco | 2.48% | $32.89K | $14.98B | -17.12% | 71 Outperform | |
| American Financial Group | 2.45% | $32.47K | $10.78B | 2.74% | 67 Neutral |
SMAP Technical Analysis
Positive
―
Price Trends
26.30
Positive
25.80
Positive
25.40
Positive
Market Momentum
0.08
Positive
58.89
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For SMAP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.50, equal to the 50-day MA of 26.30, and equal to the 200-day MA of 25.40, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 58.89 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SMAP.
SMAP Peer Comparison
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents